Researchers discovered that certain helpful bacteria called Bifidobacterium bifidum can protect kidneys from damage by improving gut health. They tested 39 different bacterial strains and found two that produce a special compound called ILA. When they gave these bacteria to mice with kidney disease, one strain (called ZL.1) significantly improved kidney function and reduced inflammation. The bacteria work by activating a protective pathway in the body that reduces harmful inflammation in both the gut and kidneys. This research suggests that taking the right probiotics might become a new way to help people with chronic kidney disease, though more human studies are needed.
The Quick Take
- What they studied: Whether special probiotic bacteria could help treat chronic kidney disease by improving gut health and reducing inflammation
- Who participated: Laboratory mice with artificially induced kidney disease were used to test the bacteria. The researchers screened 39 different bacterial strains before selecting the most promising ones
- Key finding: One bacterial strain (ZL.1) significantly improved kidney damage, restored gut barrier function, and reduced harmful inflammation by producing a compound called ILA that activates protective pathways in the body
- What it means for you: This research suggests that specific probiotics might help protect kidneys in people with chronic kidney disease, but human studies are still needed before doctors can recommend this treatment. People with kidney disease should talk to their doctor before trying new supplements
The Research Details
Scientists started by testing 39 different strains of helpful bacteria to find which ones produced the most of a special compound called ILA (indole-3-lactic acid). They used a laboratory technique called HPLC to measure this compound in each strain. They identified two promising strains and confirmed through genetic testing that both had the genes needed to make ILA.
Next, they tested these bacteria in mice that had been given a chemical to damage their kidneys, mimicking chronic kidney disease in humans. The mice received the bacteria as a treatment, and researchers measured changes in kidney function, gut health, inflammation levels, and the types of bacteria living in their guts.
The researchers used advanced genetic analysis to understand exactly how the bacteria protected the kidneys. They looked at which genes were activated and which inflammatory pathways were turned off when the bacteria were present.
This research approach is important because it combines multiple scientific techniques to understand not just whether something works, but exactly how it works. By identifying the specific compound (ILA) and the specific pathway it activates (AHR signaling), researchers can develop better treatments and predict which patients might benefit most. This also explains why some bacterial strains help while others don’t—it’s about producing the right compounds.
This study used laboratory mice rather than humans, which means results may not directly apply to people yet. The researchers did use advanced genetic sequencing and metabolite analysis, which are reliable scientific methods. The study was well-designed with clear measurements of kidney function and inflammation. However, animal studies are typically considered preliminary evidence that needs to be confirmed in human trials before clinical use.
What the Results Show
The ZL.1 bacterial strain showed strong protective effects in mice with kidney disease. Kidney damage improved significantly, meaning the organs were functioning better and showing less scarring (fibrosis). The bacteria also restored the protective barrier in the gut, which normally prevents harmful substances from entering the bloodstream.
The researchers found that the ZL.1 strain produced high levels of ILA, a compound made from tryptophan (an amino acid in food). This ILA activated a protective pathway in the body called AHR signaling. When this pathway was activated, it turned off a harmful inflammatory response called NLRP3 inflammasome activation, which is known to damage both the gut and kidneys.
The gut bacteria composition also improved in treated mice. Beneficial bacteria (Muribaculaceae) increased while harmful bacteria (Dubosiella) decreased. This shift toward a healthier bacterial community likely contributed to the overall improvement in kidney function and reduced inflammation.
The FL228.1 strain, while also producing ILA, showed only moderate protective effects. This suggests that the amount of ILA produced matters—more ILA appears to mean better kidney protection. The researchers also found that the specific genetic makeup of the bacteria (having the Aldh gene) was essential for producing ILA. Without this gene, the bacteria couldn’t make the protective compound.
Previous research has shown that people with kidney disease often have unhealthy gut bacteria (dysbiosis) and that the gut and kidneys are connected through multiple pathways. This study builds on that knowledge by identifying a specific mechanism: the ILA-AHR pathway. Earlier studies suggested probiotics might help kidney disease, but this research explains why certain strains work better than others. The focus on tryptophan metabolism is relatively new and represents an advance in understanding how diet and bacteria interact to protect kidney health.
The biggest limitation is that this study used mice, not humans. Mouse studies often don’t translate directly to human medicine—what works in mice may not work the same way in people. The study didn’t test different doses of the bacteria or how long treatment would need to continue. It also didn’t examine whether the bacteria would work in people taking other medications or with different types of kidney disease. The sample size of mice wasn’t specified in the abstract, making it hard to assess statistical reliability. Finally, this is a single study, so results need to be confirmed by other research teams before clinical recommendations can be made.
The Bottom Line
Based on this research alone, probiotics cannot yet be recommended as a treatment for chronic kidney disease in humans. The evidence is promising but preliminary (moderate confidence level). People with chronic kidney disease should continue following their doctor’s prescribed treatments. If interested in probiotics, discuss with your nephrologist (kidney doctor) before starting any supplement, as some probiotics may not be appropriate for kidney disease patients.
This research is most relevant to people with chronic kidney disease and their doctors, as well as researchers developing new kidney disease treatments. It’s also interesting for people interested in how gut bacteria affect overall health. However, people should NOT self-treat with probiotics based on this study alone. Those with advanced kidney disease should be especially cautious, as some probiotics can be harmful when kidney function is severely impaired.
In the mouse studies, improvements in kidney function and inflammation were measured over several weeks. If this treatment eventually becomes available for humans, it would likely take months to see meaningful improvements in kidney function. However, changes in gut bacteria composition might occur within weeks. Any human trials would need to track patients for at least several months to assess safety and effectiveness.
Want to Apply This Research?
- Users could track daily probiotic intake (type and amount), kidney function markers if they have access to lab results (creatinine levels, eGFR), and digestive symptoms (bloating, regularity, energy levels). This creates a personal record to discuss with their doctor.
- Once this treatment becomes available, users could set reminders to take their probiotic supplement at the same time daily, log any digestive changes, and track how they feel overall. They could also monitor dietary tryptophan intake (found in foods like turkey, cheese, nuts, and seeds) since the bacteria work with this amino acid.
- Long-term tracking should include regular kidney function tests (as recommended by their doctor), changes in energy levels and digestive health, and any side effects. Users should maintain a log to share with their healthcare provider at regular appointments to assess whether a probiotic treatment is working.
This research is preliminary and was conducted in laboratory mice, not humans. The findings cannot yet be applied to human treatment of chronic kidney disease. People with chronic kidney disease should not start probiotic supplements without consulting their nephrologist or primary care doctor, as some probiotics may be inappropriate or harmful depending on kidney function level and other medications. This article is for educational purposes only and should not replace professional medical advice. Always discuss new treatments with your healthcare provider before starting them.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.